Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 15/20 | 0.55 |
| ▸ | MMEL1 | Q495T6 | 5/20 | 0.50 |
| ▸ | ACE | P12821 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18874680 | 1.00 | MME (0.55) | MMEMMEL1ACEKDM4EALDH1A1 | |
| SCHEMBL16930454 | 1.00 | MME (0.55) | MMEMMEL1ACEKDM4EALDH1A1 | |
| SCHEMBL18874681 | 0.93 | MMEL1 (0.49) | MMEMMEL1ACE | |
| SCHEMBL16941027 | 0.91 | MME (0.49) | MMEMMEL1ACE | |
| SCHEMBL16941514 | 0.91 | MME (0.49) | MMEMMEL1ACE | |
| SCHEMBL20306304 | 0.90 | MMEL1 (0.47) | MMEMMEL1ACE | |
| SCHEMBL11969730 | 0.90 | MME (0.54) | MMEMMEL1ACECTSL | |
| SCHEMBL18411073 | 0.90 | MME (0.54) | MMEMMEL1ACECTSL | |
| SCHEMBL11970064 | 0.90 | MME (0.54) | MMEMMEL1ACECTSL | |
| SCHEMBL11969971 | 0.89 | MME (0.70) | MMEMMEL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099678-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-12-12 | — | — | EP | disclosed |